Krystal Biotech, Inc. (NASDAQ:KRYS) Forecasted to Post Q2 2024 Earnings of $0.37 Per Share

Krystal Biotech, Inc. (NASDAQ:KRYS) – HC Wainwright increased their Q2 2024 earnings per share estimates for Krystal Biotech in a research report issued on Monday, May 6th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings per share of $0.37 for the quarter, up from their prior estimate of $0.10. HC Wainwright has a “Buy” rating and a $200.00 price objective on the stock. The consensus estimate for Krystal Biotech’s current full-year earnings is $1.82 per share. HC Wainwright also issued estimates for Krystal Biotech’s Q3 2024 earnings at $0.31 EPS, Q4 2024 earnings at $0.18 EPS and FY2024 earnings at $0.89 EPS.

Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Monday, May 6th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.20 by ($0.17). The business had revenue of $45.25 million for the quarter, compared to analysts’ expectations of $47.37 million. During the same quarter last year, the firm posted ($1.76) earnings per share. The company’s revenue for the quarter was up 452400.0% compared to the same quarter last year.

Several other research analysts have also recently issued reports on the company. Guggenheim upped their price target on Krystal Biotech from $130.00 to $175.00 and gave the company a “buy” rating in a report on Tuesday, February 27th. Stifel Nicolaus reaffirmed a “buy” rating and set a $204.00 price objective (up from $178.00) on shares of Krystal Biotech in a research report on Tuesday, April 16th. William Blair restated an “outperform” rating on shares of Krystal Biotech in a research note on Tuesday, February 27th. Finally, Citigroup increased their price target on shares of Krystal Biotech from $160.00 to $195.00 and gave the stock a “buy” rating in a research note on Tuesday, February 27th. Nine research analysts have rated the stock with a buy rating, According to MarketBeat.com, Krystal Biotech has an average rating of “Buy” and a consensus target price of $171.00.

Krystal Biotech Stock Down 2.5 %

Shares of Krystal Biotech stock opened at $157.68 on Wednesday. Krystal Biotech has a fifty-two week low of $86.03 and a fifty-two week high of $189.97. The business has a fifty day simple moving average of $168.76 and a 200-day simple moving average of $134.27. The firm has a market cap of $4.50 billion, a price-to-earnings ratio of 1,971.25 and a beta of 0.91.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, CAO Kathryn Romano sold 8,087 shares of the company’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $136.91, for a total value of $1,107,191.17. Following the sale, the chief accounting officer now directly owns 12,556 shares in the company, valued at $1,719,041.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $170.96, for a total transaction of $4,274,000.00. Following the transaction, the insider now directly owns 1,550,882 shares in the company, valued at approximately $265,138,786.72. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CAO Kathryn Romano sold 8,087 shares of the firm’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $136.91, for a total value of $1,107,191.17. Following the completion of the transaction, the chief accounting officer now owns 12,556 shares in the company, valued at $1,719,041.96. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 38,087 shares of company stock worth $6,210,591. 14.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Krystal Biotech

Several hedge funds have recently bought and sold shares of KRYS. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Krystal Biotech by 111.8% in the third quarter. China Universal Asset Management Co. Ltd. now owns 718 shares of the company’s stock valued at $83,000 after buying an additional 379 shares during the period. Quest Partners LLC bought a new position in shares of Krystal Biotech during the 4th quarter worth approximately $127,000. Pier 88 Investment Partners LLC acquired a new position in Krystal Biotech in the 4th quarter valued at about $145,000. Fox Run Management L.L.C. bought a new stake in Krystal Biotech in the 3rd quarter valued at $219,000. Finally, Headlands Technologies LLC bought a new stake in Krystal Biotech in the 1st quarter valued at about $291,000. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).